ADCT ADC Therapeutics SA: Company Short-Term Debts

Symbol and logo of brand ADC Pharma (ADCT)

The share price retrospective for ADC Therapeutics (ADCT) demonstrates the asset's dynamics, with a value of 0.00. ADC Therapeutics creates potent antibody-drug conjugates for the targeted treatment of lymphomas, reducing the toxicity of hematologic tumor therapies. The company's operations are based on the development of innovative drugs and diagnostic systems to combat oncology. The startup's environmental profile is limited to laboratory chemical disposal regulations and the energy efficiency of its workspaces.

ADCT ADC Therapeutics S.A. Company Short-Term Loans and Borrowings (07/04/2022 - 10/31/2026)

ADC Pharma - analytical breakdowns and key metrics (ADCT)

- stock price and consensus target price:
Stock Price ADC Therapeutics SA|ADCT - Consensus Target
- company stock capitalization data:
Market Capitalization ADC Therapeutics SA|ADCT - Total Enterprise Value
- business book valuation details:
Net Assets per Single Share ADC Therapeutics|ADCT - Accounting Value of Company|Market Cap to Net Assets Ratio adctherapeutics.com|ADCT - Aggregate Asset Value
- debt and liquidity details:
Total Debt to Capital ADC Therapeutics|ADCT - Long-Term Debt to Equity|Short-Term Debt to Equity ADC Therapeutics|ADCT - Company Debts|Debt to Book Capitalization Ratio ADC Therapeutics SA|ADCT - Long-Term Debt|Company Short-Term Debt ADC Therapeutics|Quick Ratio adctherapeutics.com
- earnings and multiples data:
ADCT - Company Profit
Fundamental company valuation:ADCT - ADC Therapeutics SA
Manufactured products of ADC Therapeutics

This metric is calculated by summing all liabilities with a maturity horizon of up to one year based on financial statements. It determines the current pressure on the issuer's liquidity and solvency. For ADC Therapeutics (ADCT), this volume is critical when financing the development of the PBD platform and advancing Zynlonta. The balance of borrowings affects the biotech's financial stability within the lymphoma segment. The dynamics of these liabilities on the short-term debt chart reflect the business's real margin of safety.

Main competitors

TG Therapeutics - Company Short-Term Debts|Arcellx Inc (ACLX) - Company Current Liabilities|IRON: Company Short-Term Debts|Short-Term Debt Syndax Corp (SNDX)|Company Short-Term Debt Kura Oncology, Inc.|FHTX: Company Short-Term Loans and Borrowings|Company Current Liabilities VOR (Vor Biopharma)|NKTX (nkartatx.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts COEP (Coeptis Therapeutics, Inc.)|Actinium Corp - Company Short-Term Debt|ESLA - Company Short-Term Debt|CASI: Company Short-Term Debt|markertherapeutics.com (MRKR) - Company Short-Term Debt|Short-Term Debt IN8bio Inc. (INAB)|Company Short-Term Debt Eterna Therapeutics, Inc.|Short-Term Debt GT Biopharma Corporation GTBP|Company Short-Term Debts APTO|biopathholdings.com - Company Short-Term Indebtedness|Company Short-Term Debts MEIP (MEI Pharma)|Company Short-Term Debts Vincerx Pharma Inc. VINC